scholarly journals Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

2020 ◽  
Vol 9 (9) ◽  
pp. 2967
Author(s):  
Anne M. Macpherson ◽  
Simon C. Barry ◽  
Carmela Ricciardelli ◽  
Martin K. Oehler
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Current Knowledge ◽  
Tumour Microenvironment ◽  
Tumour Immunology ◽  
The Us ◽  
Cancer Types ◽  
Cancer Immunotherapeutic ◽  
Cancer Immunotherapies

Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.

Determination of HE4-mediated roles in tumor immune system modulation in Epithelial Ovarian Cancer (EOC)

2015 ◽  
Vol 139 (3) ◽  
pp. 591
Author(s):  
Anze Urh ◽  
Nicole Romano ◽  
KyuKwang Kim ◽  
Jennifer Ribeiro ◽  
Christina Raker ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Immune System Modulation

scholarly journals Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer

2018 ◽  
Vol 120 (2) ◽  
pp. 207-217 ◽  
Author(s):  
Kelly L. Singel ◽  
Kassondra S. Grzankowski ◽  
A. N. M. Nazmul H. Khan ◽  
Melissa J. Grimm ◽  
Anthony C. D’Auria ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mitochondrial Dna ◽  
Epithelial Ovarian Cancer ◽  
Tumour Microenvironment ◽  
Advanced Epithelial Ovarian Cancer

scholarly journals Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

2018 ◽  
Vol 14 ◽  
pp. 174550571775069 ◽  
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Drug Administration ◽  
Clinical Data ◽  
Food And Drug Administration ◽  
Gynecologic Oncology ◽  
Brca Gene ◽  
Polymerase Inhibitors ◽  
The Us ◽  
Relevant Role

There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and particularly (although not exclusively) in the setting of known mutations in the BRCA gene. This review will briefly highlight the biological rational for the use of poly (ADP-ribose) polymerase inhibitors in this malignancy, followed by summary of currently available clinical data supporting the delivery of agents approved by the US Food and Drug Administration for non-investigative use.

P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system

2019 ◽  
Author(s):  
T Baert ◽  
C Landolfo ◽  
J Ceusters ◽  
G Thirion ◽  
A Van Hoylandt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Crosstalk between the mitochondrial fission protein, Drp1, and the cell cycle is identified across various cancer types and can impact survival of epithelial ovarian cancer patients

Oncotarget ◽  
2016 ◽  
Vol 7 (37) ◽  
pp. 60021-60037 ◽  
Author(s):  
Deepak Kumar Tanwar ◽  
Danitra J. Parker ◽  
Priyanka Gupta ◽  
Brian Spurlock ◽  
Ronald D. Alvarez ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Mitochondrial Fission ◽  
Cancer Types

scholarly journals EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3019
Author(s):  
Artur Słomka ◽  
Tudor Mocan ◽  
Bingduo Wang ◽  
Iuliana Nenu ◽  
Sabine Urban ◽  
...  
Keyword(s):  
Current Knowledge ◽  
Tumour Progression ◽  
Cell Communication ◽  
Tumour Microenvironment ◽  
Host Immune System ◽  
Mediated Communication ◽  
Cell Content ◽  
Cytokines And Chemokines ◽  
Liver Cancers ◽  
Cancer Types

For more than a decade, extracellular vesicles (EVs) have been in focus of science. Once thought to be an efficient way to eliminate undesirable cell content, EVs are now well-accepted as being an important alternative to cytokines and chemokines in cell-to-cell communication route. With their cargos, mainly consisting of functional proteins, lipids and nucleic acids, they can activate signalling cascades and thus change the phenotype of recipient cells at local and systemic levels. Their substantial role as modulators of various physiological and pathological processes is acknowledged. Importantly, more and more evidence arises that EVs play a pivotal role in many stages of carcinogenesis. Via EV-mediated communication, tumour cells can manipulate cells from host immune system or from the tumour microenvironment, and, ultimately, they promote tumour progression and modulate host immunity towards tumour’s favour. Additionally, the role of EVs in modulating resistance to pharmacological and radiological therapy of many cancer types has become evident lately. Our understanding of EV biology and their role in cancer promotion and drug resistance has evolved considerably in recent years. In this review, we specifically discuss the current knowledge on the association between EVs and gastrointestinal (GI) and liver cancers, including their potential for diagnosis and treatment.

scholarly journals Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016

2020 ◽  
Vol 3 (9) ◽  
pp. e2017517 ◽  
Author(s):  
Anne T. Knisely ◽  
Caryn M. St. Clair ◽  
June Y. Hou ◽  
Fady Khoury Collado ◽  
Dawn L. Hershman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Median Survival ◽  
Primary Treatment ◽  
Advanced Stage ◽  
The Us
Sign in / Sign up

Export Citation Format

Share Document